119 results
8-K
EX-99.1
BTTX
Better Therapeutics Inc
11 Mar 24
Regulation FD Disclosure
9:01am
BT-001 Usability Diabetes Cohort Validation Study a 238 Study (T2D) (T2D) 473 448 BT-001 Payer Employee 23 95 a RWE Studies 885 Cohort Study BT-002
424B3
BTTX
Better Therapeutics Inc
10 Jan 24
Prospectus supplement
7:01am
Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate
8-K
EX-10.1
BTTX
Better Therapeutics Inc
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate
424B3
3yb iav70k
28 Dec 23
Prospectus supplement
9:23pm
8-K
EX-10.1
dtav84ud7svjk 389sbc
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
PRE 14A
z7wzeg edfgp
6 Oct 23
Preliminary proxy
4:15pm
424B5
0cxngee4ts
9 Aug 23
Prospectus supplement for primary offering
4:37pm